Impact Of Pulmonary Arterial Hypertension Pah

Merck Announces Fourth- Quarter and Full -Year 2021 ...

the treatment of pulmonary arterial hypertension(PAH) . Sotatercept is in Phase 3 trials as an add-on to current standard of care for the treatment of PAH. • Merck presented results from two early Phase 1 clinical studies evaluating its investigational oral PCSK9 inhibitor (MK-0616) at the American Heart Association Scientific Sessions 2021.

  Arterial, Hypertension, Pulmonary, Of pulmonary arterial hypertension